Jacobs & Co’s Idexx Laboratories IDXX Stock Holding History

Jacobs & Co’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-300	Closed	-$202K	–	126
2025 Q4	$202K	Buy	+300	New	+$204K	0.02%	124

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jacobs & Co's IDXX Position: Q1 2026 in Review

Jacobs & Co sold out of Idexx Laboratories (IDXX) in Q1 2026, closing a stake of 300 shares — an estimated $202K sold.

Jacobs & Co first reported a position in IDXX in Q4 2025 and held it in 1 quarter. The position peaked at $202K in Q4 2025. 1,316 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

Jacobs & Co reported no remaining Idexx Laboratories position as of Q1 2026 after selling out during the quarter.
Jacobs & Co sold 300 Idexx Laboratories shares in Q1 2026, an estimated $202K.
Jacobs & Co first reported a position in Idexx Laboratories in Q4 2025 and held it in 1 quarter.
Jacobs & Co's Idexx Laboratories position peaked at $202K in Q4 2025.
1,316 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Jacobs & Co's 13F filing for Q1 2026, filed 7 Apr 2026.